LFG
GLUE icon

Larson Financial Group’s Monte Rosa Therapeutics GLUE Stock Holding History

Larson Financial Group’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.38K Hold
181
– – ﹤0.01% 2830
2026
Q1 		$2.98K Hold
181
– – ﹤0.01% 2833
2025
Q4 		$2.84K Hold
181
– – ﹤0.01% 2682
2025
Q3 		$1.34K Hold
181
– – ﹤0.01% 2834
2025
Q2 		$816 Sell
181
-228
-56% -$1.02K ﹤0.01% 2712
2025
Q1 		$1.9K Buy
+409
New +$2.51K ﹤0.01% 2182

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Larson Financial Group's GLUE Position: Q2 2026 in Review

Larson Financial Group held its Monte Rosa Therapeutics (GLUE) position steady in Q2 2026 at 181 shares worth $4.38K. The position accounts for ﹤0.01% of the portfolio, ranked #2830.

Larson Financial Group first reported a position in GLUE in Q1 2025 and has held it in 6 quarters since. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Larson Financial Group held 181 shares of Monte Rosa Therapeutics worth $4.38K as of Q2 2026.
  • Larson Financial Group left its Monte Rosa Therapeutics share count unchanged in Q2 2026.
  • Monte Rosa Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #2830 holding.
  • Larson Financial Group first reported a position in Monte Rosa Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.